partnering

News
Roivant logo

Roivant joins RNA splicing push with Eisai deal

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugm

News
A new approach to COVID-19 treatment

Mesoblast pummelled as Novartis exits COVID deal

Novartis has opted out of a collaboration with Mesoblast to develop its stem cell-based therapy remestemcel-L as a treatment for COVID-19, prompting a slump in the biotech's share price.&nb